Puma Biotechnology, Inc. (PBYI) focuses on developing and commercializing innovative products to improve cancer care. The company's lead product, NERLYNX (neratinib), is an oral prescription medicine for treating early-stage and metastatic HER2-positive breast cancer. Puma in-licenses drug candidates that have completed initial clinical testing, advances them through development, and commercializes them mainly in the U.S. through third-party manufacturers and distributors.
In the competitive oncology landscape, Puma occupies a niche with NERLYNX driving most of its revenue, alongside royalty income. From what I see, the company's strong fundamentals—three straight years of profitability and a cash position of nearly $100 million—have provided resilience amid biotech sector volatility. This positioning in HER2-targeted therapies has contributed to the recent recovery as demand stabilizes and pipeline catalysts come into view.
In the last 30 days, PBYI stock has climbed +16%, moving from around $5.90-$6.20 to approximately $6.90-$7.00. The path was volatile at first, with a dip after Q4 earnings in late February, followed by a steady recovery and a trend-driven upswing that broke above key moving averages.
Over the past quarter, shares advanced +14%, starting from roughly $6.20 to current levels. The performance included an early post-earnings pullback, then range-bound consolidation, and a bullish breakout—mirroring improved trends in small-cap biotech. Daily volume averaged 400,000 shares, which has supported this upward trajectory. I also checked this using Tickeron’s AI Screener to compare PBYI against industry peers.
The 30-day rally in PBYI came from a mix of technical signals and renewed operational confidence. Shares crossed above the 200-day moving average in mid-March—a classic bullish indicator in technical analysis that drew in momentum traders. This followed a sharp drop after Q4 2025 earnings in late February, where results beat estimates with adjusted EPS of $0.29 against $0.24 expected and revenues up 15% to $75.5 million. However, weak 2026 guidance of $214-$221 million in total revenue sparked initial selling.
The recovery picked up as investors focused on sustained NERLYNX sales of $55 million in Q4 and progress in alisertib trials, including upcoming data presentations. Analyst commentary stayed neutral but emphasized profitability, which helped sentiment. Broader biotech optimism, supported by stable interest rates, provided a tailwind for the sector.
The +14% quarterly gain for PBYI built on impressive full-year 2025 results: $228 million in total revenue, $31 million net income ($0.61 diluted EPS), and debt reduced to $22.5 million. Institutional interest increased, with short interest at 10.71% of float, creating potential for a squeeze.
While Q4 beats initially weighed on shares due to guidance missing consensus, other elements drove the rebound: 28% year-over-year quarterly revenue growth, positive feedback from conferences like TD Cowen, and alisertib progress in breast and lung cancer trials. Macro tailwinds, such as biotech index gains and expectations for lower rates, enhanced Puma's edge over peers. In my view, investors have started valuing the company's cash flow positivity, especially with ongoing M&A activity in the industry.
In my research process, I often turn to Tickeron’s Trending AI Robots to identify top-performing AI trading bots from hundreds available. This page highlights bots scanning thousands of tickers across strategies like day trading, swing trading, and long-term investing, based on recent performance metrics, win rates, average returns, and market relevance. It helps me pinpoint automated tools that match specific risk levels and timeframes, whether for momentum or value plays, with transparent stats and backtests. One thing that stands out is how it streamlines stock analysis with data-driven automation.
Looking forward, I'm watching Q1 2026 earnings closely for the NERLYNX sales trajectory and Phase 2 data readouts for alisertib in hormone receptor-positive breast cancer and small cell lung cancer. Upcoming conferences could bring partnership updates. Macro elements like Fed rate decisions and the biotech funding environment may influence sentiment. Risks involve guidance changes or trial setbacks, while catalysts include label expansions or oncology buyouts. Keeping an eye on volume and moving averages will be essential for price signals.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
The Aroon Indicator for PBYI entered a downward trend on November 20, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 202 similar instances where the Aroon Indicator formed such a pattern. In 162 of the 202 cases the stock moved lower. This puts the odds of a downward move at 80%.
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PBYI as a result. In 69 of 97 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 71%.
The Moving Average Convergence Divergence Histogram (MACD) for PBYI turned negative on October 29, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 35 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 73%.
PBYI moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for PBYI crossed bearishly below the 50-day moving average on November 10, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 71%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PBYI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 78%.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 10 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 13 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +5.01% 3-day Advance, the price is estimated to grow further. Considering data from situations where PBYI advanced for three days, in 261 of 292 cases, the price rose further within the following month. The odds of a continued upward trend are 89%.
PBYI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron PE Growth Rating for this company is 4 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 44 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 46 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating steady price growth. PBYI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 72 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PBYI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Valuation Rating of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.074) is normal, around the industry mean (3.596). P/E Ratio (15.566) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (2.105) is also within normal values, averaging (443.347).
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
operates as a development stage company which develops biopharmaceuticals used for the treatment of cancer
Industry Biotechnology